Fabbio, M.B.A. has
served on our board since January 2, 2018.
Fabbio is currently the Chief Financial Officer of Progenics Pharmaceuticals, Inc. a public
biotech company. Prior to joining Progenics in November 2015, he was Chief
Financial Officer of electroCore LLC, a privately-held bioelectric
medicine healthcare company, and Vice President, Finance for NPS
Pharmaceuticals, Inc., a publicly traded, global rare disease company that was
acquired by Shire. Mr. Fabbio has more than 20 years of financial leadership
experience in both public and private life science and pharmaceutical companies
in various roles, including: Vice President, Finance of Catalent Pharma
Solutions Inc.; Chief Financial Officer of Ikano Therapeutics Inc.; senior
corporate finance, commercial and transactional roles at Sanofi; and Corporate
Controller for Biomatrix Inc., a publicly traded biotechnology company that was
acquired by Genzyme.
received his B.B.A. in accounting at Pace University and M.B.A. from the Stern
School of Business at New York University.
© BeyondSpring Inc. All Rights Reserved.